英国肿瘤药物的卫生技术评估评价研究及其启示

Study on Health Technology Assessment on Cancer Drugs in UK and Its Implications

在肿瘤药物我国医保准入进程持续加速的大背景下,如何有效平衡肿瘤药物医保准入与基金可持续性成为当前我国医保管理所面临的棘手问题,引入卫生技术评估的方法十分必要。本文通过剖析英国肿瘤药物卫生技术评估的临床价值审评与成本-效益评估两大核心审评要素,借鉴其有益思路与方法,提出建立第三方HTA机构、明确参照药物标准、加强模型法应用等政策建议。

Under the background of accelerating medical insurance access of cancer drugs in China,how to effectively balance medical insurance access of cancer drugs and fund sustainability has become a thorny problem in medical insurance management institutions.It is necessary to introduce health technology assessment.This paper analyzes the 2 core elements of clinical value evaluation and cost-effectiveness evaluation of health technology evaluation of cancer drugs in the UK,and draws on its useful ideas and methods to puts forward some policy suggestions on establishing a third-party HTA organization,making clear the reference drug standards,strengthening the application of model method etc.